Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Phase 1 Study to Evaluate the Safety and Effects of a Single Dose of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Adults.

25. August 2026 aktualisiert von: Shanghai Peptidstar Therapeutics Limited

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HCXT-2001 Tablets and HCXT-2001 Tablets(A) After Single Administration in Healthy Adult Participants.

The goal of this intervention study is to assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Participants. The main parameters it aims to answer are: Does a single dose of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in healthy participants impact the Safety, Tolerability, Pharmacokinetics, and Immunogenicity profiles? This study will be a - randomized, double blind, placebo-controlled study.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

40

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Auckland
      • Takapuna, Auckland, Neuseeland, 0622
        • Momentum Clinical Research (MCR)
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene

Akzeptiert gesunde Freiwillige

Ja

Beschreibung

Inclusion Criteria:

  1. Body weight ≥ 50 kg for males and ≥ 45 kg for females, and body mass index (BMI) between 18.0 and 30.0 kg/m2 (inclusive) at screening.
  2. In good general health as determined by medical history, vital signs, physical examination, 12-lead ECG, laboratory tests (including hematology, blood biochemistry, coagulation function tests, urinalysis, stool routine tests), chest X-ray, etc., with results either within normal limits or assessed by the investigator as not clinically significant.
  3. Has been fully informed about the study, voluntarily agrees to participate, and has signed the ICF.
  4. The participant and their sexual partner(s) have no plans for conception from 2 weeks before screening until 6 months after the last dose of the investigational product, and agree to voluntarily using one or more highly effective non-pharmacological contraceptive methods and no intention of donating sperm or eggs during this period.

Exclusion Criteria:

  1. History or presence of immunological diseases.
  2. Women who are pregnant or are breastfeeding.
  3. Any prior or current disease or abnormality that, in the investigator's judgment, is clinically significant and may interfere with the conduct or interpretation of the study, including but not limited to neurological, cardiovascular, renal, hepatic, gastrointestinal, respiratory, hematological, endocrine, oncologic, pulmonary, immunological, psychiatric, or cerebrovascular conditions.
  4. Individuals who smoked, consumed coffee, St. John's Wort (hypericum perforatum), grapefruit, pomelo juice, or cranberry juice, and/or engagement in strenuous physical activity within 24 hours prior to dosing, which in the opinion of the investigator may affect drug absorption, distribution, metabolism, or excretion.
  5. Suspected or known allergy to any component of the investigational product, or any documented history of allergies
  6. Previous surgical procedures that may affect the results of the clinical study or gastric/abdominal surgery that may impact oral drug absorption; or recent major gastric/abdominal surgery of any kind within 12 weeks prior to screening or during study. With the exception of minor surgeries that in the opinion of the investigator/medical monitor, such as excision of subcutaneous lipomas.
  7. Having taken any prescription medication, over-the-counter drug, herbal medicine, or dietary supplement within 14 days prior to dosing or within five half-lives of the first administration, except for the condition without impact on the study outcomes as determined by the investigator. Occasional paracetamol less than 1000 mg for minor ailments is permitted if required.
  8. Non-physiological blood loss or donation of more than 400 mL of blood within 2 months prior to screening, receipt of a blood transfusion within 2 months prior to screening; or plans to donate blood during the study or within 60 days after the last dose.
  9. Participation in any investigational drug or medical device clinical trial with administration of the investigational product or device intervention within 3 months or five half-lives prior to screening.
  10. History of alcohol abuse, or consumption of more than 14 alcohol units per week within 6 months prior to screening , or unwillingness to abstain from alcohol during the study, or a positive alcohol test at screening.
  11. History of smoking (average daily cigarette consumption ≥ 5 cigarettes within 3 months prior to screening) or unwillingness to abstain from smoking during the study.
  12. History of drug abuse, use of illicit drugs within 3 months prior to the study, or a positive urine drug screen.
  13. Infection (including chronic or localized infection) within 7 days prior to screening, or a history of recurrent infections with underlying conditions predisposing to infections, or a history of opportunistic infections.
  14. Positive test result for any of the following: hepatitis B surface antigen, syphilis-specific antibody, hepatitis C antibody, or human immunodeficiency virus antibody.
  15. Those who have received any vaccine within 1 month prior to screening, or who are scheduled to receive any vaccine during the study or within 1 month after study completion.
  16. Having any other factors that, in the opinion of the investigator, may affect the study results or interfere with the participant's participation in the clinical study.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: HCXT-2001 Tablets - Cohort 1
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
Experimental: HCXT-2001 Tablets - Cohort 2
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
Placebo-Komparator: HCXT-2001 Tablets - Placebo Cohort 1
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
Experimental: HCXT-2001 Tablets(A) - Cohort 3
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
Experimental: HCXT-2001 Tablets(A) - Cohort 4
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
Placebo-Komparator: HCXT-2001 Tablets(A) - Placebo Cohort 3
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
Placebo-Komparator: HCXT-2001 Tablets - Placebo Cohort 2
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
Placebo-Komparator: HCXT-2001 Tablets(A) - Placebo Cohort 4
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
Number of participants with AEs,SEAs, with abnormal - vital signs,physcial examinations,clinical laboratory results ,12-lead ECGs and stool routine tests
Zeitfenster: Day 1 to Day 50
Day 1 to Day 50

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Maximum concentration of the drug (Cmax) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Zeitfenster: Day 1 to Day 50
Will be calculated using the non-compartmental analysis.
Day 1 to Day 50
Time to maximum concentration (Tmax) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Zeitfenster: Day 1 to Day 50
Will be calculated using the non-compartmental analysis.
Day 1 to Day 50
Area under the plasma concentration-time curve (AUC, including AUC0-t and AUC0-inf, etc.) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Zeitfenster: Day 1 to Day 50
Will be calculated using the non-compartmental analysis.
Day 1 to Day 50
Apparent volume of distribution (Vd/F) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Zeitfenster: Day 1 to Day 50
Will be calculated using the non-compartmental analysis.
Day 1 to Day 50
Apparent clearance (CL/F) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A)
Zeitfenster: Day 1 to day 50
Will be calculated using the non-compartmental analysis.
Day 1 to day 50
Plasma elimination half-life (t1/2) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Zeitfenster: Day 1 to Day 50
Will be calculated using the non-compartmental analysis.
Day 1 to Day 50
Mean residence time (MRT) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Zeitfenster: Day 1 to Day 50
Will be calculated using the non-compartmental analysis.
Day 1 to Day 50
Anti-drug antibodies (ADAs) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Zeitfenster: Day 1 to Day 50
Day 1 to Day 50
Neutralizing antibodies (Nabs) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Zeitfenster: Day 1 to Day 50
Day 1 to Day 50

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

14. August 2026

Primärer Abschluss (Geschätzt)

10. November 2026

Studienabschluss (Geschätzt)

10. November 2026

Studienanmeldedaten

Zuerst eingereicht

25. August 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

25. August 2026

Zuerst gepostet (Tatsächlich)

28. August 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

28. August 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

25. August 2026

Zuletzt verifiziert

1. Juli 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • HCXT-2001-PS-1-02

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .